Clinical trials: Blood
HCV Infection
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
- Trial name
- NCT00696904
- Testing
- ABT-333
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- AbbVie
Human Immunodeficiency Viruses
Evaluation of Diagnostic HIV Ag/Ab Combo Assay
To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV).
- Trial name
- NCT00933933
- Testing
- ARCHITECT HIV Ag/Ab Combo
- Where
- 13 sites in United States
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Multiple Myeloma and Malignant Lymphoma
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.
- Trial name
- NCT05007652
- Testing
- KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor)
- Where
- 21 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial name
- NCT04684108
- Testing
- SG301
- Where
- 14 sites in China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with…
- Trial name
- NCT05769608
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 104 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mineralys Therapeutics Inc.
Hepatitis C, Liver Disease
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e.
- Trial name
- NCT01970904
- Testing
- Alisporivir, Ribavirin, Peg-IFNα2a
- Where
- 25 sites in Germany, Poland and 2 more
- Volunteers
- 147 people
- Sponsor
- Debiopharm International SA
Multiple Myeloma
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."
- Trial name
- NCT00424047
- Testing
- CC-5013 plus dexamethasone
- Where
- 69 sites in Australia, Austria and 13 more
- Volunteers
- 351 people
- Sponsor
- Celgene
HIV Infections
A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels
IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal…
- Trial name
- NCT00613249
- Testing
- Dapivirine Gel 4750, 0.05%, 2.5g, Dapivirine Gel 4789, 0.05%, 2.5g
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Hepatitis C
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
- Trial name
- NCT02496078
- Testing
- Daclatasvir, Asunaprevir
- Where
- 29 sites in China, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Bristol-Myers Squibb
Acute Leukemia
Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and…
- Trial name
- NCT00823316
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Medipost Co Ltd.
Iron Overload Due to Repeated Red Blood Cell Transfusions
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.
- Trial name
- TWICE (NCT03802916)
- Testing
- Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage)
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- ApoPharma
Hepatitis B
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y
This study will evaluate the immunogenicity and safety of different formulations of the HBV-MPL vaccine administered according to a 2-dose schedule and compare it to that of Engerix™-B administered according to a 3-dose schedule…
- Trial name
- NCT00698906
- Testing
- HBV-MPL vaccine, Engerix™-B
- Where
- Austria
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test
Prospective multicenter sample collection and testing study.
- Trial name
- NCT02638311
- Where
- 3 sites in United States
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Trinity Biotech
Purpura, Thrombocytopaenic, Idiopathic
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems.
- Trial name
- NCT00442871
- Testing
- eltrombopag
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with standard doses of PEGASYS plus…
- Trial name
- NCT00412334
- Testing
- Copegus, peginterferon alfa-2a [Pegasys]
- Where
- 22 sites in France
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C virus (HCV)-infected adults who are undergoing…
- Trial name
- NCT02728206
- Testing
- SOF/VEL
- Where
- New Zealand
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Factor XIII Deficiency
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00945906
- Testing
- FXIII Concentrate (Human) (FXIII)
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- CSL Behring
HIV Infections
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals
Clinical specimens are required from HIV positive individuals with viremia controlled by antiretroviral therapy to complete process development for a genetically modified autologous T cell product, AGT103-T.
- Trial name
- NCT03215004
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- American Gene Technologies International Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.